1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Sage/Biogen Depression Data Likely To Prolong Commercial Debate

 
• By Alaric DeArment

Data from the Phase III CORAL study of zuranolone showed the drug missing efficacy at day 15, which may dampen its appeal in the real-world setting.

DEPRESSION miserable depressed , Depression and its consequences, Depressed emotions concept , alone in depression - Image
Sage/Biogen announced results from the Phase III CORAL study of zuranolone in major depressive disorder • Source: Shutterstock

Debate over the commercial viability of Sage Therapeutics, Inc./Biogen, Inc.’s zuranolone isn’t getting any quieter as additional data rolls in. The Phase III CORAL study in major depressive disorder (MDD) met its primary endpoint of rapid onset of anti-depressant effect, with an acceptable safety and tolerability profile, but missed a key endpoint on durability.

The companies unveiled the CORAL data on 16 February, saying that the trial met its primary endpoint of a rapid...

More from Neurological

More from Therapy Areas

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By Kevin Grogan

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 
• By Alaric DeArment

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By Kevin Grogan

The Austrian firm is delisting from the NASDAQ and closing down.